• PemOla
    Share

Trial Status

In Development

Cancer Type

Pancreatic Cancer

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Protocol Title

A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/Mb.

Purpose of the Study

Pancreatic adenocarcinoma (PDAC) is one of the 10 most common cancer types. Despite modern interventions, outcomes have changed little in the last 50 years and PDAC is projected to be the second most common cause of cancer death by 2030. Up to 80% of patients are diagnosed with the disease too late for surgery and median survival with metastatic pancreatic adenocarcinoma (mPDAC) is under 1 year even with optimal chemotherapy. Developing more effective treatments for mPDAC is a global unmet need. Precision medicine approaches to PDAC are attractive given the heterogeneity of this disease and the poor outcomes with conventional chemotherapy.

Currently, immunotherapy is not routinely established as an effective treatment for patients with metastatic pancreatic cancer. The study aims to understand whether patients with metastatic pancreatic cancer will respond well to immunotherapy comprising of the two drugs, pembrolizumab and olaparib.

DETAILED INFORMATION AVAILABLE

More detailed information to come.

STUDY CHAIRS

Dr Dan Croagh
A/Prof Sumitra Ananda

FUNDING

Philanthropic funding
Tour De Cure Grant
PanKind
Epworth Medical Foundation Grant

Trial Status

In Development

Cancer Type

Pancreatic Cancer

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.